Phase 3 Parkinson's Disease Trial, Completed

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You are a male with prostate cancer (specifically adenocarcinoma) that has been confirmed by a lab test, and it is not the small cell type.
• Your cancer has spread to other parts of the body, shown by either 2 or more spots on a bone scan or spread to internal organs seen on a CT or MRI scan.
• You are willing to continue hormone-suppressing therapy (to lower testosterone) throughout the study, or you have already had both testicles surgically removed.
• You are generally well enough to carry out light activity and care for yourself (a standard doctor's fitness rating of 0 or 1, checked within 10 days of joining).
• If you are already taking bone-strengthening medication, you have been on a stable dose before joining the trial.
• Your kidneys, liver, and other organs are working well enough as shown by recent blood tests.
• You are able to provide a recent tissue sample (biopsy taken within the last 12 months) from a tumor area that has not been previously treated with radiation (or a bone biopsy if your cancer is mainly in the bones).
• You agree not to donate sperm and to either avoid sexual intercourse or use contraception for the entire treatment period and for at least 120 days after your last dose.
• You agree to use a condom during any sexual activity where ejaculate could be passed to another person.

Who may not be able to join:

• You have another cancer that is still growing or has needed active treatment in the past 3 years.
• You have an autoimmune disease (where the immune system attacks the body) that needed medical treatment in the past 2 years.
• You have been diagnosed with an immune system deficiency, or you are currently taking long-term steroid medication.
• You had major surgery or a procedure on your prostate (not including a biopsy) within the past 28 days and have not fully recovered.
• You have a digestive condition that affects how your body absorbs medication, or you are unable to swallow tablets or capsules.
• You currently have an active infection, including tuberculosis, that requires treatment.
• You have a history of lung inflammation (not caused by infection) that needed steroid treatment, or you currently have lung inflammation.
• You have an active HIV, hepatitis B, or hepatitis C infection.
• Your cancer has spread to your brain or the lining around it.
• You have a history of seizures or a condition that makes seizures more likely.
• You lost consciousness at any point in the 12 months before screening.
• You have had a heart attack or uncontrolled chest pain in the past 6 months, or you have moderate-to-severe heart failure.
• Your blood pressure is too low (below 86 systolic) or uncontrolled and too high (above 170 systolic or 85 diastolic) at your screening visit.
• You have a history of serious irregular heartbeats.
• You have had an allergic reaction to either of the study drugs (pembrolizumab or enzalutamide) or their ingredients.
• You previously received hormone-suppressing therapy for more than 39 months for non-spreading prostate cancer, or received it within the past 9 months, or your cancer got worse while on that therapy.
• You have previously been treated with newer hormone-blocking drugs such as abiraterone, enzalutamide, apalutamide, or darolutamide.
• You have previously received certain types of immunotherapy drugs that work on the PD-1 or PD-L1 pathway, or similar immune-targeting treatments.
• You received a live vaccine within 30 days before joining the trial.
• Your bone scan shows an extremely widespread pattern throughout your bones (called a "superscan") (confirm with trial site).
• You have received an organ or tissue transplant from another person.
• You are planning to father children from the time of screening until 120 days after your last dose.
• You have already received drug treatment, radiation, or surgery for your metastatic prostate cancer, with some limited exceptions (confirm with trial site for details on whether short-term hormone therapy, limited palliative radiation, or a short course of chemotherapy with docetaxel may still allow you to qualify).

Important: Always verify eligibility with the trial site directly before applying.